Blog
RSS FeedPosted by Michael Wonder on 17 Aug 2017
Generic drug makers feel pinch as prices crumble
17 August 2017 - Intensified competition hurts copycat pharma groups while buyers drive harder bargain. ...
Posted by Michael Wonder on 17 Aug 2017
House Democrats start multiple sclerosis drug price probe
18 August 2017 - Biogen, Sanofi, Roche among drug makers who received letter. ...
Posted by Michael Wonder on 17 Aug 2017
Lynparza receives additional and broad approval in the US for ovarian cancer
17 August 2017 - Newly-approved tablet formulation means improved patient convenience. ...
Posted by Michael Wonder on 17 Aug 2017
A start-up suggests a fix to the health care morass
16 August 2017 - If you watched the drama in Washington last month, you may have come away with the ...
Posted by Michael Wonder on 17 Aug 2017
FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukaemia
17 August 2017 - The U.S. FDA today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or ...
Posted by Michael Wonder on 17 Aug 2017
Exelixis submits U.S. supplemental new drug application for Cabometyx (cabozantinib) for the treatment of previously untreated advanced kidney cancer
16 August 2017 - Cabometyx is the first therapy to demonstrate a clinically meaningful and statistically significant progression-free survival benefit over ...
Posted by Michael Wonder on 17 Aug 2017
Portola Pharmaceuticals announces AndexXa (andexanet alfa) biologics license application resubmission accepted for review by U.S. FDA
15 August 2017 - Portola Pharmaceuticals today announced that the U.S. FDA has found its resubmitted biologics license application for ...
Posted by Michael Wonder on 17 Aug 2017
Association of reference pricing with drug selection and spending
17 August 2017 - In the United States, prices for therapeutically similar drugs vary widely, which has prompted efforts by public ...
Posted by Michael Wonder on 16 Aug 2017
Trump tweets up a storm on drug prices but delivers little change
15 August 2017 - President Donald Trump’s condemnation on Twitter Monday of Merck CEO Kenneth Frazier for what he called ...
Posted by Michael Wonder on 16 Aug 2017
What’s harder than making copycat biotech drugs? Selling them
15 August 2017 - Payer pacts, wary patients vex the market for biosimilar drugs. ...
Posted by Michael Wonder on 16 Aug 2017
Flimsy evidence behind many FDA approvals
16 August 2017 - Many drugs granted accelerated approval by the U.S. FDA lack clear evidence of safety and effectiveness, ...
Posted by Michael Wonder on 16 Aug 2017
Trump threat on Obamacare would boost deficit by $194 billion
16 August 2017 - Administration has said it may halt payments to insurers. ...
Posted by Michael Wonder on 16 Aug 2017
Lipocine announces FDA acknowledgement of Tlando ("LPCN 1021") NDA resubmission; PDUFA goal date, 8 February 2018
14 August 2017 - Lipocine today announced that the U.S FDA has acknowledged receipt of the company's new drug application ...
Posted by Michael Wonder on 15 Aug 2017
Institute for Clinical and Economic Review releases draft evidence report on cognitive and mind-body therapies for treatment of chronic low back and neck pain
15 August 2017 - Public comment period now open until 12 September; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 15 Aug 2017
Characteristics of pre-approval and post-approval studies for drugs granted accelerated approval by the US Food and Drug Administration
15 August 2017 - The FDA granted accelerated approval to 22 drugs for 24 indications. ...